BMC Anesthesiology
August 26, 2026
Mao Li, Wen Wen, Xiang Wen
Postoperative depression and anxiety are common in elderly patients undergoing joint replacement surgery and may affect recovery. Esketamine has rapid antidepressant effects, but evidence for combined perioperative use remains limited, particularly in elderly patients undergoing joint replacement surgery. This study evaluated the association between combined perioperative esketamine exposure...
Journal of Neurophysiology
August 26, 2026
An EEG-Based Evaluation of Antidepressant Effects of Ketamine Enantiomers and Metabolites in Monkeys.
The Journal of Clinical Psychiatry
August 26, 2026
The Prescriber's Guide to Oral Ketamine for Patients With Major Depressive Illness: Principles and Practice.
Healthcare
August 26, 2026
Mostafa A. Sayed Ali, Palanisamy Amirthalingam, Hanan Alshareef et al.
Background/Objectives: This study evaluated the real-world effectiveness and safety of intranasal esketamine plus oral antidepressants compared with venlafaxine-based oral antidepressant therapy in adults with moderate-to-severe treatment-resistant depression (TRD). Methods: This retrospective cohort study used electronic medical records from a mental health hospital between January 2023 and...
Frontiers in Psychiatry
August 26, 2026
Jon Berner
Background Multiple preclinical and clinical reports suggest that rapamycin augmentation may increase the safety and efficacy of ketamine treatment. Population variability in patient biochemical gain-of-function and phenotypic admixtures, however, has slowed initial investigations into patient selection and dose finding. Methods A single-center, retrospective chart review identified 101...
Pharmacological Research
August 26, 2026
Mattia Giovenzana, Noemi Nicosia, Stefano Spinosa et al.
Neurodevelopmental disorders (NDDs) comprise a heterogeneous group of conditions arising from altered brain development and leading to impairments in social, cognitive, emotional, and motor domains. Clinical manifestations are highly variable in severity and symptom profile, reflecting the complex and multifactorial etiology of NDDs. Available treatments are limited to early behavioral...
Tạp chí Y học Cộng đồng
August 25, 2026
Long Tiến Nguyễn, T. Trần, Cường Mạnh Đặng et al.
Bối cảnh: Ketamine là thuốc gây mê phân ly đang ngày càng bị lạm dụng với mục đích giải trí. Tổn thương đường tiết niệu do ketamine đã được mô tả rộng rãi, tuy nhiên sự hiện diện bất thường tại nhiều cơ quan trên cắt lớp vi tính (CLVT) chưa được báo cáo đầy đủ trong y văn. Ca bệnh: Chúng tôi báo cáo trường hợp bệnh nhân nam 34 tuổi nhập viện vì sốt kéo dài, tiểu lắt nhắt và tăng men gan. Can...
Neuropsychiatrie
August 25, 2026
Nicolas Schmelzle, Katrin Neubacher, Paul L. Plener et al.
BACKGROUND: Depressive symptoms and suicidality are highly prevalent in adolescents with early-onset psychosis (EOP) and often remain refractory to standard treatment. While S‑ketamine is an established treatment for treatment-resistant depression in adults (TRD), its use in primary psychotic disorders remains scarce due to risk of exacerbation of psychotic symptoms. CASE PRESENTATION: We...
The Canadian journal of urology
August 21, 2026
Derrick Tsang, Ioannis Loufopoulos, Konstantinos Kapriniotis et al.
Ketamine is a potent anaesthetic drug that has been used for decades. Ketamine abuse is an increasingly common problem, particularly among young people. Over one quarter of ketamine users will have at least one bothersome urological symptom, with heavier and longer use leading to potentially irreversible damage to the lower and upper urinary tract. Hence, this study carried out a narrative...
Frontiers in Nutrition
August 21, 2026
Agnieszka Mechlińska, Mariusz S. Wiglusz, Jakub Słupski et al.
This study evaluated the acute and short-term effects of repeated ketamine treatment on appetite in adult inpatients with treatment-resistant mood disorders, including major depressive disorder and bipolar disorder. Appetite, hunger, and desire to eat were assessed using the Visual Analog Scales (VAS) and the Simplified Nutritional Appetite Questionnaire (SNAQ) at baseline and at multiple time...
Journal of Affective Disorders
August 20, 2026
Suicidal ideation covaries with depressive severity during six-month real-world esketamine treatment in a cohort enriched for borderline personality disorder.
International Immunopharmacology
August 19, 2026
Ali A Albariqi, Dalia A. Nawwar, Weam W Ibrahim et al.
Baricitinib, a selective JAK1/JAK2 inhibitor with established anti-inflammatory properties, has demonstrated therapeutic efficacy in several autoimmune and inflammatory diseases. This study aimed to investigate the neuroprotective potential of baricitinib in a ketamine-induced rat model of schizophrenia. Specifically, the study examined its effects on behavioral deficits, neurochemical...
Cells
August 18, 2026
Bernard Kordas
The reversible effects of general anesthesia can be used to examine how brain activity changes during transitions into and out of altered conscious states. Such changes are commonly tracked using behavioral responses, electroencephalographic recordings, and measures of functional connectivity. These measures, however, reflect processes occurring at lower levels of organization, including the...
Expert Review of Neurotherapeutics
August 18, 2026
Mario Pinzi, Alessandro Cuomo, Maria Beatrice Rescalli et al.
INTRODUCTION: Acute suicidal ideation in major depressive disorder (MDD) is a psychiatric emergency requiring rapid risk assessment, containment, and treatment. Conventional monoaminergic antidepressants have delayed onset, leaving an interval during which severe depressive distress persists. Intranasal esketamine, a rapid-acting N-methyl-D-aspartate receptor antagonist, is approved for MDD...
Translational Psychiatry
August 18, 2026
Marvin Sören Meiering, David Weigner, Matti Gärtner et al.
Rumination has been associated with aberrant dynamics of a coactivation pattern (CAP) comprising the default mode (DMN) and frontoparietal (FPN) networks. Ketamine exerts rapid antidepressant effects and may influence these dynamics via glutamatergic mechanisms. In a randomized, double-blind, placebo-controlled fMRI study, we investigated ketamine's effects on dynamic CAPs associated with...
Der Nervenarzt
August 17, 2026
Stefan Vestring, Katharina Domschke, Claus Normann
Ketamine has been established as an anesthetic agent for decades. Around the turn of the millennium initial clinical studies demonstrated that subanesthetic doses of ketamine can exert antidepressant effects in treatment-resistant depression. These findings established the concept of an effective glutamatergic antidepressant treatment and initiated a paradigm shift. For many years, intravenous...
August 17, 2026
Tychique T. Wasolua, Morgan S. Hardy, Tanner J. Bommersbach et al.
INTRODUCTION: Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used, yet synthesized data on cumulative safety remain limited. This systematic review evaluated long-term safety of both agents. METHODS: MEDLINE, PsycINFO, Embase, and Cochrane Library were searched from inception through...
Annals of Middle Eastern Medicine
August 15, 2026
Abdulaziz Turki Alqabli, Aisha Abdullah Ateeq Alharbi, Wajan Majed Alahmadi et al.
Background: Adolescent major depressive disorder (MDD) is associated with substantial impairment, suicide risk, and limited response to standard treatments. Intravenous ketamine has rapid antidepressant effects in adults, but pediatric evidence remains limited. This systematic review and meta-analysis evaluated the short-term efficacy and safety of intravenous ketamine for adolescents with MDD,...
Journal of Affective Disorders
August 15, 2026
Michał Walaszek, Wiesław Jerzy Cubała, Zofia Kachlik et al.
Anhedonia, a core symptom of major depressive disorder (MDD), is associated with illness severity, suicide risk, poor functioning, and predicts poor response to antidepressants. While no treatments are approved, ketamine and esketamine show promise in reducing anhedonia. This study examines clinical and sociodemographic features linked to anhedonia treatment response in treatment-resistant...
medRxiv
August 14, 2026
Annette M Braxton, Christina Driver, Daniel F. Hermens et al.
preprint
Abstract Major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) are prevalent, chronic, and disabling mental health conditions which are difficult to treat. Ketamine has demonstrated effect for improving depression and PTSD symptoms independently but reports often overlook focused comorbid improvement of these symptoms within individuals. To address this, we assessed...